# Study of LP-184 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct05933265/  
OnCo record `nct05933265` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Olaparib, Ipilimumab and Nivolumab in triple-negative breast cancer, non-small-cell lung cancer and pancreatic ductal adenocarcinoma, run by Lantern Pharma Inc., active and no longer recruiting.

## Summary

Study of LP-184 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05933265 by Lantern Pharma Inc., with 64 participants enrolled, started 2023-06-09 and due to reach its primary completion in 2026-07-28. Interventions recorded: LP-184, Olaparib and Nivolumab & Ipilimumab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05933265
- Phase: 1/2
- Setting: A Phase 1/2 Dose Escalation and Cohort Expansion Study of LP-184 in Patients With Advanced or Metastatic Solid Tumors
- Sponsor: Lantern Pharma Inc.
- Enrolled: 64

## Sources

- ClinicalTrials.gov NCT05933265: https://clinicaltrials.gov/study/NCT05933265

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [LP-184](https://onco.cc/drugs/lp-184/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Olaparib](https://onco.cc/drugs/olaparib/)

---
JSON: https://onco.cc/api/v1/entities/nct05933265.json